{
  "docId": "019de075-2875-74d4-8194-84b6aaf5cb83",
  "docSlug": "17078b9c485724b1d98591e3cd98aa3e",
  "documentTitle": "Kymera | Investor Presentation Deck | 60 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 57,
  "pageCount": 60,
  "prevPage": 56,
  "nextPage": 58,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide title mentions KT-333, but the content refers to KT-253 throughout; this is likely a typo in the source deck.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de075-2875-74d4-8194-84b6aaf5cb83/57",
  "deckHref": "/decks/019de075-2875-74d4-8194-84b6aaf5cb83",
  "deckJsonHref": "/decks/019de075-2875-74d4-8194-84b6aaf5cb83.json",
  "deckAnchorHref": "/decks/019de075-2875-74d4-8194-84b6aaf5cb83#slide-57",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.7,
        "x": 0.25,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Dose escalation flow chart showing DLx to MTD/RP2D for solid tumors and DLy to MTD/RP2D for AML, leading to Phase 1b expansion cohorts.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3250c52-a2af-493a-8ad5-6582e9c65732",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.65,
        "x": 0.3,
        "y": 0.75
      },
      "kind": "list",
      "text": "Phase 1a: Initiate dose escalation in ST/L and AML. Phase 1b: Initiate expansion in R/R AML and select solid tumors/lymphomas.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "24a1ea83-46c1-4953-b982-12345f3aa53b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.25,
        "x": 0.02,
        "y": 0.2
      },
      "kind": "list",
      "text": "Hematological Malignancies: AML identified as initial indication; patient stratification strategy; preclinical support for ALL and P53WT lymphomas. Solid Tumors: Preclinical studies identified sensitive types.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2c1070c-4b2c-4f43-a8d3-e3b5dffaa7bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.58,
        "y": 0.55
      },
      "kind": "table",
      "text": "Key Objectives table comparing Primary, Secondary, and Exploratory endpoints for Phase 1a and Phase 1b.",
      "attrs": null,
      "subkind": "kpi",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f56be54-ea80-4bda-818a-5e0dc4ea2a83",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "KT-253: Phase 1, Multicenter, Dose-Escalation and Expansion Trial to Evaluate KT-333 in Adult Patients with Liquid and Solid Tumors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bde867db-85f0-4bf4-90f1-530f3d79aa0a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}